My watch list  


Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
CAS number 81403-80-7
ATC code G04CA01
PubChem 2092
DrugBank APRD00490
Chemical data
Formula C19H27N5O4 
Mol. mass 389.449 g/mol
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Half life 10 hours
Excretion Fecal (69%) and renal (24%)
Therapeutic considerations
Pregnancy cat.

B2(AU) B(US)

Legal status

POM(UK) -only(US)

Routes Oral

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed by Sanofi Aventis under the brand name Uroxatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.


Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation or to patients who are taking medications known to prolong the QT interval.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Alfuzosin". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE